FRAXA Grant/Fellowship Contract

INTRODUCTION

FRAXA Research Foundation offers a grants and fellowships program designed to encourage research aimed at finding a specific treatment for fragile X syndrome. FRAXA's goal is to bring practical treatment into current medical practice as quickly as possible; therefore, preference will be given to research projects that have a clear practical application and the results of which will be shared with other qualified researchers in a timely fashion.

• **FRAXA Clinical Trial Grants** are reviewed and awarded on a revolving basis; there is no application deadline. They are flexible in amount and duration. They must involve human subjects with fragile X syndrome. Highest priority is given to clinical trials of potentially disease-modifying therapeutics which have been validated in fragile X animal models.

• **FRAXA Fellowships** of $50,000 per year for 2 years are offered to support individuals to pursue research on fragile X.

• **Renewals** are reviewed on a rolling basis. All grants and fellowships require yearly renewal. Renewal applications are due 60 days before the start date of the additional year of funding.

A brief Letter of Intent to Michael Tranfaglia, MD mtranfaglia@fraxa.org is essential for all new applications.

ELIGIBILITY FOR GRANTS/FELLOWSHIPS

Any university, hospital, or other non-profit lab in the world may apply. No geographical preferences are employed. No grants or fellowships are payable to individuals.

ACCEPTABLE COSTS

Fellowships allow for a flexible use of funding; salary support for any personnel with graduate-level experience is permitted. Supply budgets are also allowed.

These limitations do not apply to Clinical Trial Grants. FRAXA reserves the right to cover any item if explicitly authorized by FRAXA's Board of Directors. However, FRAXA is unable to pay for indirect costs under any circumstances.

Fellowships and grants are awarded for one year (unless explicitly authorized for another term) and may be renewed for a second year based on satisfactory progress. If a project is not initiated within nine months of the date the award is made, the award must be reauthorized by FRAXA's Board of Directors.
AMENDMENT OF POLICIES

FRAXA Research Foundation reserves the right to modify its policies governing grants at any time. The Grantee agrees to abide by any changes or to terminate the grant within 30 days of the time when such changes become effective. Failure to abide by the policies governing grants shall be considered sufficient grounds for cancellation of a grant or refusal to consider any pending application by the grantee.

PROHIBITION OF DISCRIMINATION

No person shall be excluded from participation in or denied the benefits of any program or activity or receiving financial assistance from FRAXA because of race, ethnic origin, religion, sex, or sexual orientation.

HUMAN AND ANIMAL SUBJECTS

Human subjects studied in the course of research conducted under a grant are under no circumstances a responsibility of FRAXA. Human subjects in a program supported by FRAXA shall be volunteers in any survey, study or procedure. Research involving human subjects must have Institutional Review Board approval. If animals are used in the proposed study, written certification must be provided to FRAXA indicating that proper treatment, care, and humane conditions have been provided. Research involving animal subjects must have Institutional Animal Care and Use Committee approval.

OBLIGATIONS OF THE GRANTEE

In accepting a grant, the applying institution undertakes that it will:

• Submit within 90 days following the end of the award period to FRAXA a complete final scientific report on the work pursued. On awards of more than one year duration, a yearly scientific report will be expected.

• Supply an accounting of funds received from FRAXA and expenditures made in such detail and in such manner as may meet Internal Revenue Service procedures.

PUBLICATION AND DISSEMINATION OF RESULTS

FRAXA’s purpose in providing grants is to accelerate progress towards treatment for fragile X. Therefore, in accepting an award, the Principal Investigator undertakes to:
• Publish the results of the work pursued in the primary literature in a timely fashion. Once published, the reagents, methods, materials, and products of the work must be made available immediately to other qualified researchers, subject to Grantee’s material transfer agreement as applicable.

• Recognize the support of FRAXA in any published article resulting from the work pursued with a credit line reading “Supported in part by a grant from FRAXA Research Foundation.”

• Recognize the support of FRAXA in any presentation of the work at professional meetings and conferences.

Before a project can start, the scientists funded will work with FRAXA to develop a non-confidential lay description of the project for fraxa.org and social media. The grantee institution, Principal Investigator, and Fellow will cooperate fully with FRAXA in announcements through the news media of grants awarded and in materials prepared to publicize work under the grant. FRAXA will publish periodic descriptions and updates on funded projects in its publications, social media, and website.

INTELLECTUAL PROPERTY

"Invention" means all discoveries, improvements, and inventions arising from this grant together with all related data, results, and information. Title to any Invention shall reside with the grantee institution. The grantee institution will notify FRAXA promptly after identifying any Invention that the grantee institution believes is patentable and will supply FRAXA, in confidence, with copies of that Invention. For a patented Invention conceived and reduced to practice that is subsequently licensed under this grant, FRAXA and the grantee institution will negotiate in good faith to enter into a royalty sharing agreement consistent with the grantee institution's policies and procedures solely for the equitable distribution of net income from the Invention, taking into consideration the level of funding provided.

Grantee institution shall make reasonable efforts to license the Invention for commercial development to a third-party. Unless otherwise agreed to by FRAXA, the grantee institution or other title holder shall agree that, if it or its designee or licensee has not taken effective steps to bring the Invention to practical or commercial application through licensing or otherwise on terms that are reasonable in the circumstances within three years after issuance of the patent claiming Invention, FRAXA shall receive an automatic grant of a non-exclusive, indefinite, fully paid-up, royalty-free, transferable, irrevocable world-wide license (with the right to sub-licenses) to advance such Invention within the field of fragile X research, diagnosis, and treatment.
FRAXA CONTRACT SIGNATURE PAGE

Project Title:

Requested Start Date:

We accept the conditions specified above. We acknowledge and accept the provision that results of this research must be shared with other qualified researchers in a timely fashion.

Signature - Principal Investigator         PI name - please print         Date

Signature - Manager
Office of Grants & Contracts

Name - please print        Title        Date

Office of Grants & Contracts Address, Contact Name, Phone, Email:

Institution Tax ID:

Award should be made payable to:

and mailed to (if different from Office of Grants and Contracts):